A2 Refereed review article in a scientific journal
New Promising Targets for Imaging in Cardiovascular Diseases
Authors: Ståhle, Mia; Popescu, Cristina; Rischpler, Christoph; Zhang, Han; Massalha, Samia; Lopes, Leonor; Rominger, Axel; Caobelli, Federico
Publisher: Elsevier
Publication year: 2025
Journal: Seminars in Nuclear Medicine
Journal name in source: Seminars in Nuclear Medicine
Volume: 55
Issue: 5
First page : 812
Last page: 828
ISSN: 0001-2998
eISSN: 1558-4623
DOI: https://doi.org/10.1053/j.semnuclmed.2025.05.006
Publication's open availability at the time of reporting: Open Access
Publication channel's open availability : Partially Open Access publication channel
Web address : https://doi.org/10.1053/j.semnuclmed.2025.05.006
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/499582737
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide, driven by complex and dynamic molecular processes such as inflammation, fibrosis, metabolic dysregulation, thrombosis, and vascular remodeling. While conventional imaging techniques provide valuable anatomical and functional information, they fail to capture these underlying pathophysiological mechanisms at the molecular level. Molecular imaging, particularly with PET and SPECT, offers the potential to noninvasively visualize and quantify these processes, enabling earlier diagnosis, better risk stratification, and more precise treatment guidance. Despite substantial progress in clinical cardiology, there is a growing need for novel radiotracers that can target key disease-driving mechanisms beyond traditional perfusion or viability imaging. Emerging radiopharmaceuticals now enable the assessment of myocardial fibrosis (e.g., collagen-targeted and MMP-targeted tracers), cardiomyocyte stress responses (e.g., oxidative stress, unfolded protein response, endothelin signaling), and metabolic alterations (e.g., fatty acid, ketone, and glucose metabolism). Additionally, new tracers are being developed for thrombosis, vascular inflammation, plaque instability, and even for innovative targets such as cellular senescence and gut-derived inflammatory pathways. These developments reflect a paradigm shift towards imaging-driven phenotyping of cardiovascular disease. This review provides a comprehensive overview of the latest advances in molecular imaging tracers for cardiovascular applications, with a focus on their biological rationale, preclinical and clinical evidence, and translational challenges. We categorize tracers by their mechanistic targets and highlight their potential for integration into precision cardiology.
Downloadable publication This is an electronic reprint of the original article. |  |
